Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PAK1 is a serine/threonine protein kinase and a member of the p21-activated kinases (PAKs), which are critical effectors linking Rho family GTPases—specifically Cdc42 and Rac—to cytoskeletal reorganization and nuclear signaling. It plays essential roles in regulating cell motility, morphology, gene expression, cell cycle progression, survival, angiogenesis, DNA repair, hormone sensitivity, and metabolism. Mutations or dysregulation of PAK1 have been linked with several diseases, including intellectual developmental disorder, breast cancer, and acute myeloid leukemia. It is also implicated in oncogenesis generally, viral pathogenesis, cardiovascular dysfunctions, and neurological disorders.
Kinase inhibition; induction of differentiation/apoptosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on p21 (RAC1) Activated Kinase 1 (PAK1).